JP2018528200A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528200A5
JP2018528200A5 JP2018510406A JP2018510406A JP2018528200A5 JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5 JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5
Authority
JP
Japan
Prior art keywords
ring
independently
acceptable salt
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510406A
Other languages
English (en)
Japanese (ja)
Other versions
JP6877407B2 (ja
JP2018528200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/048698 external-priority patent/WO2017035354A1/en
Publication of JP2018528200A publication Critical patent/JP2018528200A/ja
Publication of JP2018528200A5 publication Critical patent/JP2018528200A5/ja
Application granted granted Critical
Publication of JP6877407B2 publication Critical patent/JP6877407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510406A 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物 Expired - Fee Related JP6877407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (3)

Publication Number Publication Date
JP2018528200A JP2018528200A (ja) 2018-09-27
JP2018528200A5 true JP2018528200A5 (cg-RX-API-DMAC7.html) 2019-09-12
JP6877407B2 JP6877407B2 (ja) 2021-05-26

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510406A Expired - Fee Related JP6877407B2 (ja) 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物

Country Status (17)

Country Link
US (2) US10017512B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341374A1 (cg-RX-API-DMAC7.html)
JP (1) JP6877407B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180043810A (cg-RX-API-DMAC7.html)
CN (1) CN108137607B (cg-RX-API-DMAC7.html)
AR (1) AR105836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016311426B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003588A2 (cg-RX-API-DMAC7.html)
CA (1) CA2995997A1 (cg-RX-API-DMAC7.html)
HK (1) HK1255330A1 (cg-RX-API-DMAC7.html)
IL (1) IL257702A (cg-RX-API-DMAC7.html)
MX (1) MX2018002407A (cg-RX-API-DMAC7.html)
PH (1) PH12018500397A1 (cg-RX-API-DMAC7.html)
RU (1) RU2744974C2 (cg-RX-API-DMAC7.html)
TW (1) TW201713665A (cg-RX-API-DMAC7.html)
WO (1) WO2017035354A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801881B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN111936138B (zh) * 2018-02-05 2024-03-08 深圳市原力生命科学有限公司 作为ep4受体拮抗剂的杂二环化合物
JP2021519297A (ja) * 2018-03-28 2021-08-10 フォチョン・ファーマシューティカルズ・リミテッドFochon Pharmaceuticals, Ltd. Trkキナーゼ阻害剤としての大環状化合物
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
ES3013815T3 (en) * 2019-02-27 2025-04-15 Ferro Therapeutics Inc Compounds with ferroptosis inducing activity and methods of their use
HUE064283T2 (hu) 2019-04-12 2024-02-28 Blueprint Medicines Corp Az (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il) piperazinil)-pirimidin-5-il)etán-1-amin kristályos formái és elõállítási eljárásai
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266519C (en) * 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
MXPA06011423A (es) * 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2010352577A1 (en) * 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US20150218652A1 (en) * 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9556181B2 (en) * 2013-02-01 2017-01-31 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE067779T2 (hu) 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3259264B1 (en) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Similar Documents

Publication Publication Date Title
RU2018110379A (ru) Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
JP2014520898A5 (cg-RX-API-DMAC7.html)
FI4355749T3 (fi) Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
JP2013522292A5 (cg-RX-API-DMAC7.html)
JP2017537080A5 (cg-RX-API-DMAC7.html)
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
RU2018122089A (ru) Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
JP2015163632A5 (cg-RX-API-DMAC7.html)
BR112014027190A2 (pt) pirrolobenzodiazepinas
JP2019535720A5 (cg-RX-API-DMAC7.html)
PH12017502334A1 (en) Polycyclic amide derivative as cdk9 inhibitors
JP2019514863A5 (cg-RX-API-DMAC7.html)
JP2019514955A5 (cg-RX-API-DMAC7.html)
JP2017530171A5 (cg-RX-API-DMAC7.html)
JP2017538677A5 (cg-RX-API-DMAC7.html)
UY32251A (es) Compuestos quimicos
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2015506985A5 (cg-RX-API-DMAC7.html)
CA2593428A1 (en) Pyrrolopyrazoles, potent kinase inhibitors
RU2012105914A (ru) Эффективные низкомолекулярные ингибиторы аутофагии и способ их применения
HK1254469A1 (zh) 稠合双环嘧啶衍生物及其用途
RU2015143717A (ru) 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины